Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

1.60
-0.0101-0.63%
Volume:14.88K
Turnover:24.04K
Market Cap:5.71M
PE:-0.33
High:1.69
Open:1.69
Low:1.56
Close:1.61
52wk High:14.64
52wk Low:1.54
Shares:3.57M
Float Shares:3.14M
Volume Ratio:0.32
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:1.39
PE(LYR):-0.24

Loading ...

Cadrenal Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Cadrenal Therapeutics Q2 EPS USD -1.14

THOMSON REUTERS
·
Aug 14

Cadrenal Therapeutics Q2 Net Loss Narrows 9.39% to $3.3 Million

Reuters
·
Aug 14

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

THOMSON REUTERS
·
Aug 14

Cadrenal Therapeutics Inc Expected to Post a Loss of $1.42 a Share - Earnings Preview

Reuters
·
Aug 07

Cadrenal Therapeutics Announces Annual Shareholder Meeting

Reuters
·
Aug 04

Cadrenal Therapeutics Highlights Phase 2 Data for CAD-1005 in Heparin-Induced Thrombocytopenia, Eyes CSA-AKI Market

Reuters
·
Aug 03

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

THOMSON REUTERS
·
Aug 03

Cadrenal Therapeutics - Expands CAD-1005 Development to Target Hit and Csa-Aki

THOMSON REUTERS
·
Aug 03

Cadrenal Aligns Pipeline into Cardiac Acute Critical Care Franchise, Shifts to Partnership-driven Model

Reuters
·
Jul 21

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
Jul 14

Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders

TIPRANKS
·
Jul 14

Cadrenal Says Phase 2 Trial of Cad-1005 Cuts Thrombotic Events by More than 25% in HIT

Reuters
·
Jul 13

Cadrenal Rises as Blood Clot Drug Cuts Risk in Mid-stage Study

Reuters
·
Jul 13

Cadrenal Therapeutics - Phase 2 Data Show over 25% Reduction in Thrombotic Events for Cad-1005

THOMSON REUTERS
·
Jul 13

Cadrenal Therapeutics - no Serious Adverse Events or Deaths Reported with Cad-1005 in Phase 2 Trial

THOMSON REUTERS
·
Jul 13

Cadrenal Therapeutics CMO James Ferguson Resigns, Effective July 31

Reuters
·
Jul 11

Cadrenal Therapeutics CEO, Chairman Quang X. Pham Disposes of 7,400 Common Shares Worth $22,422

Reuters
·
Jul 02

Cadrenal Therapeutics Prices USD 3 Million At-the-market Private Placement of Shares, Warrants

Reuters
·
Jul 01

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-the-market Under NASDAQ Rules

THOMSON REUTERS
·
Jul 01